Gist of webcast to me:
Pathological data need to be analysed and multivariate analysis performed and see specially what was the key to better results in subgroups. That can lead to two things (perhaps amongst others); (1) We know what group of patients it work in and that may lead to further knowledge about how the cell responses and then how efti can be used beyond oncology for example (2) we will know what to perhaps change/do to help with results in the subgroup that dragged the average down.
So, as i have said before, H2, or end 2020 is the time we can call this (APEC).
... and then there are other trials we are conducting ... please listen to webcast before you post about prospects of CR too.
Gist of webcast to me:Pathological data need to be analysed and...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73996 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 836970 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |